title: Curative radiotherapy in elderly patients with endometrial cancer. Patterns of relapse, toxicity and quality of life.
abstract: OBJECTIVE
  To assess survival, disease-specific survival, acute and late toxicity and quality of life in patients with curable endometrial carcinoma treated with adjuvant or primary radiotherapy at the age > or = 75 years.
  
  
  METHODS
  In a prospective study, outcome was regularly assessed in 49 patients treated between 1991 and 1995 at a median age of 78.4 years. Radiotherapy was applied using the same concept as in younger patients. Thirty-eight patients received postoperative adjuvant radiotherapy (vaginal insertions only: n = 18; external and vaginal insertions: n = 17; external radiotherapy only: n = 3), 8 patients were treated for a vaginal recurrence. Three patients received primary radiotherapy. Median pelvic dose was 39.6 Gy (ICRU) with 1.8 Gy per fraction (4 fields). Vaginal HDR radiotherapy consisted of 5 times 5 Gy at 0.5 cm depth in cases with no external radiotherapy, and of 3 times 5 Gy in addition to pelvic radiotherapy, respectively. Median follow-up was 3.2 years. The EORTC QLQ-C30 was used for self-assessment of quality of life.
  
  
  RESULTS
  Survival and disease-specific survival at 5 years was 64% and 84%, respectively. There was no pelvic or vaginal recurrence in patients with Stage IA to IIB. Patients with positive adnexa and those treated for vaginal recurrence relapsed in 50%. Two patients (4%) did not complete radiotherapy because of severe diarrhea. Grade 4 late complications were observed in 1/38 patients following adjuvant radiotherapy and in 2/8 patients treated for a recurrence. The actuarial rate of Grade 3 to 4 complications was 7% at 3 years. Quality of life was good in most cases and remained constant over time.
  
  
  CONCLUSIONS
  Elderly patients with endometrial cancer may be treated following the same guidelines as younger patients. Radiotherapy for a vaginal recurrence is less effective and more toxic.
authors.affiliation: University Hospital Zürich, Switzerland. Pia.Huguenin@dmr.usz.ch
authors.forename: P
authors.initials: P
authors.lastname: Huguenin
authors.forename: B
authors.initials: B
authors.lastname: Baumert
authors.forename: U M
authors.initials: UM
authors.lastname: Lütolf
authors.forename: E
authors.initials: E
authors.lastname: Wight
authors.forename: C
authors.initials: C
authors.lastname: Glanzmann
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001918:Brachytherapy; D018572:Disease-Free Survival; D016889:Endometrial Neoplasms / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D004717:Endometrium / Q000528:radiation effects; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000209:etiology* / Q000401:mortality; D009367:Neoplasm Staging; D010166:Palliative Care; D011788:Quality of Life; D011832:Radiation Injuries / Q000209:etiology*; D011879:Radiotherapy Dosage; D015996:Survival Rate